Case of Brugada Syndrome

Authors
Dr Rajat Shankarrao Dalal¹, Dr Anil Modak², Dr Tanuja Manohar³, Dr Nalini Humaney⁴
¹Medicine Resident, ²,³Associate Professor, ⁴Professor and HOD

Abstract
In 1992 Brugada et al. described clinical entity associated with ST segment elevation in precordial leads (V1 to V3) with incomplete or complete Right Bundle Branch Block and susceptibility to ventricular tachyarrhythmia and sudden cardiac death has been described. The disease is now know as “Brugada syndrome” (BrS). The prevalence of Brugada syndrome is unknown as mostly is goes undiagnosed. Common presentation of Brugada syndrome is syncope typically occurring at rest or during sleep (mostly seen in third or fourth decade of life). Brugada syndrome can be life threatening in some cases as tachycardia does not terminate and it may degenerate into ventricular fibrillation and leads to sudden cardiac death. Brugada syndrome is an autosomal dominant pattern of inheritance. In approximately 20% of the cases BrS is caused by mutations in the SCN5A gene on chromosome 3p21-23, encoding the cardiac sodium channel. SCN5A is a protein involved in the control of myocardial excitability. Sodium channels are heat sensitive so fever can also unmask Brugada syndrome. The use of the implantable cardioverter defibrillator (ICD) is the only therapeutic option of proven efficacy for primary and secondary prophylaxis of cardiac arrest.

39 yrs old male came with complaint of Fever with chills since last 4 days increased since day of admission associated with generalised weakness and bodyache, nausea and headache. No complaint of vomiting, loose stools, pain in abdomen No complaint chest pain, breathlessness

ON EXAMINATION
He was Febrile (100⁰ Celsius), Pulse – 86/min REG, Respiratory Rate – 16/min, BP- 120/80 mm Hg, No cyanosis, no clubbing, no lymphadenopathy.

SYSTEMIC EXAMINATION
CVS – S1 S2 Normal, No murmur
P/A –Soft, Nontender, No organomegaly
RS – Clear, air entry present bilaterally upto bases
CNS – Conscious, Oriented, No Focal Neurological Deficit
Past History
No significant past history.
No history of sudden cardiac death in family

LAB REPORTS
CBC - Hb – 12.5, TLC -5200, Platelet count – 1.09
KFT - Urea – 30.4 Creat – 1.1 Na+ - 139 K + - 3.7
LFT – Total Sr. Bilirubin – 0.9 SGOT – 29 SGPT – 27 Alkaline Phosphatase – 135 Sr. albumin – 4.7
Urine Routine and Microscopy – Nil
RBS – 135 mg/dl
CXR PA – Normal
Dengue – IgM - Positive
HRP II – Negative

Widal – Negative
USG Abdomen – Suggestive of Hepatosplenomegaly

ECG was done at the time of hospitalization, when he was febrile was suggestive of type I Brugada pattern, i.e. Incomplete RBBB with J point elevation in precordial leads. ECG also reveled ventricular ectopics.

As ECG was showing ST-T changes so CKMB was done which was 19.8.
So 2D Echo was done suggestive of RV apex and small segment of free wall of RV, near apex was dilated and dyskinetic. 2D Echo was suggestive of left persistent left SVC communicating with coronary sinus.
Patients multiple ecgs were taken when he was afebrile, in those ecgs Brugada syndrome was not seen. His subsequent Echo was also normal. So in this case, fever has unmasked BrS; as it is channelopathy and Sodium channels are heat sensitive.

Treatment given
Symptomatic treatment given to the patient with adequate hydration. Patient was asymptomatic for Brugada syndrome so no specific treatment was advised.

Review of Literature
In 1992 Brugada et al. described clinical entity associated with ST segment elevation in precordial leads (V1 to V3) with incomplete or complete Right Bundle Branch Block and susceptibility to ventricular tachyarrhythmia and sudden cardiac death has been described. The disease is now known as “Brugada syndrome” (BrS) or “Idiopathic ventricular fibrillation”. [1]

In 1998 Brugada et al. presented data on 63 patients in whom, after a mean follow up of 32 ± 34 months, 34% of previously symptomatic (syncope and/or cardiac arrest) patients had recurrence, while a first cardiac event occurred in 27% of the asymptomatic individuals. It led to implantation of implantable cardioverter defibrillator (ICD) in several young asymptomatic individual. However, a different picture is emerging from more recent epidemiological surveys. In 2000, Priori et al. showed an incidence of 16% for the recurrence of a cardiac arrest in symptomatic patients, while none of the asymptomatic individuals at enrolment had a cardiac event after three years of follow up and were left untreated. [2]

Genetic bases and Pathophysiology
Brugada syndrome is arrhythmogenic state which is inherited. It is a type of channelopathy. In 1998 CHEN identified that mutation in cardiac sodium channel gene, SCN5A, on chromosome
3p21-23 is associated with Brugada syndrome.[4] BrS is not the only phenotype linked to mutations in this gene.

Other known allelic disorders are Sick sinus syndrome & LQT3 variant of Long QT syndrome, the progressive cardiac conduction defect. In vitro expression of mutant SCN5A proteins showed that BrS is characterized by a loss of sodium channel function, whereas in LQT3 there is an excess of sodium inward current.[5,6,7]

Overlapping syndromes have been also described in association with some specific SCN5A mutations that may cause the coexistence of LQT3 and BrS in the same individuals.[8,9,10]

Unfortunately, SCN5A mutations account for approximately 20% of BrS cases.

**Clinical manifestations**

Patients generally present with syncope or sudden cardiac arrest.

Most of the patients are asymptomatic and are diagnosed on routine examination.

**Diagnosis of Brugada Syndrome**

Diagnosis of Brugada syndrome is based on ECG findings.

There are 3 types of BrS [3]

- **Type 1** – Coved ST segment elevation >2mm in V1 – V3 followed by negative T wave.
- **Type 2** – ST segment elevation >2mm with saddle back shape.
- **Type 3** – Either morphology of Type 1 or 2 with <2 mm ST segment elevation.

**Management and Risk stratification**

Brugada syndrome patients are at life – long risk of sudden cardiac death but for very long intervals (years) complete well-being is there between two cardiac events.

Therefore implanting ICD in asymptomatic patients is not advised as it is associated with remarkably impaired quality of life. But identification of subgroup of individuals is must in whom this aggressive therapeutic approach is mandatory.

Most BrS patients are either asymptomatic or are referred with one or few syncopal spells in their clinical history, risk stratification with careful evaluation of the clinical presentation is mandatory in these cases.

Patients with a history of syncope plus a spontaneously abnormal ECG (i.e. independent of the provocative test with intravenous sodium channel blockers) have an approximately 6-fold higher risk of cardiac events.

History of syncope alone was not an independent predictor of outcome.

These patients, as well as the silent gene carriers, belong to a low risk group.

Pharmacological therapies like use of quinidine are of doubtful use hence not advised.

Patients who have already experienced a cardiac arrest should receive an ICD according to treatment guidelines for Brugada syndrome.[11]

**Differential Diagnosis** –

Arrhythmogenic Right Ventricular Dysplasia / Cardiomyopathy,

Prinzmetal's Variant Angina,

Acute Pericarditis / Myocarditis,

Hypocalcaemia/Vitamin D Intoxication,

Acute Pulmonary Thromboembolism,

Transthoracic Cardioversion

Before diagnosing the patient as a case of BrS drug related causes must be excluded

Tricyclic antidepressants

Opioid analgesics: propoxyphene

Lithium

First-generation antihistamines: dimenhydrinate

Propofol

Beta-blockers propranolol

Potassium channel activators: pinacidil

Parasympathetic agonists: acetylcholine

Ergot alkaloids: ergonovine

Local anesthetics (non antiarrhythmic): bupivacaine

Cocaine

Alpha adrenergic agonists: methoxamine, noradrenaline
Conclusion
Brugada syndrome is an inherited arrhythmia syndrome associated with sudden cardiac death. Manifestations mostly occur around the age of 40, sudden cardiac nocturnal deaths are common. Fever can unmask Brugada syndrome. Asymptomatic patients are not to be treated but patient once experienced cardiac arrest must be treated with Implantable Cardiac Defibrillator (ICD).

References
1. Priori SG: Foretelling the future in Brugada syndrome: do we have the crystal ball? J Cardiovasc Electrophysiol 2001, 12:1008–1009